NEW DELHI (Wednesday, March 11, 2026) — A landmark study published in JAMA Network Open has found that a simple blood test can predict a woman’s risk of developing dementia as many as 25 years before the first clinical symptoms appear. The research, led by the University of California San Diego (UCSD), identifies the protein phosphorylated tau 217 (p-tau217) as a powerful early warning signal for future cognitive decline.
The Study: Decades of Data
Researchers analyzed data from the Women’s Health Initiative Memory Study (WHIMS), a long-term national project in the U.S. that followed thousands of cognitively healthy women.
- The Cohort: 2,766 women aged 65 to 79 who were cognitively healthy when they enrolled in the late 1990s.
- The Method: Blood samples collected at the start of the study (baseline) were analyzed decades later to measure p-tau217 levels.
- The Outcome: Over the 25-year follow-up period, researchers tracked which participants developed Mild Cognitive Impairment (MCI) or dementia.
- Key Finding: Women with the highest levels of p-tau217 at the start of the study were more than three times more likely to develop dementia compared to those with the lowest levels. In some subgroups, the risk was up to seven times higher.
What is p-tau217?
Tau is a protein that helps stabilize the structure of nerve cells in a healthy brain. In Alzheimer’s disease, tau undergoes a chemical change (phosphorylation), causing it to detach and form “tangles” that damage brain cells.
- Early Leakage: High levels of p-tau217 in the blood reflect early pathological changes in the brain that often precede memory loss by 20 to 30 years.
- Accuracy: p-tau217 is currently considered one of the most reliable and specific blood-based biomarkers for Alzheimer’s pathology, outperforming other variants like p-tau181.
Factors That Influence Risk
The study revealed that the predictive power of p-tau217 is not uniform across all women and is influenced by several biological and medical factors:
| Risk Factor | Impact on p-tau217 Prediction |
| Age | Higher p-tau217 levels were a stronger predictor for women over 70 than for younger participants. |
| Genetics | The association was significantly stronger in carriers of the APOE ε4 gene (a major genetic risk factor for Alzheimer’s). |
| Hormone Therapy | p-tau217 was more predictive in women who were randomized to estrogen plus progestin therapy versus those on a placebo. |
| Race | The association with dementia was stronger in White participants than in Black participants, though combining the biomarker with age improved prediction for both groups. |
Why This is “Game-Changing”
According to first author Dr. Aladdin H. Shadyab, this long lead time provides a critical window for intervention.
- Prevention: Early identification allows for lifestyle modifications (diet, exercise, sleep) that can delay symptom onset.
- Monitoring: High-risk individuals can be monitored more closely using advanced neuroimaging.
- Clinical Trials: This test can help identify ideal candidates for trials of new Alzheimer’s drugs that are most effective when administered during the early, asymptomatic stages of the disease.
Sources
- Shadyab, A. H., et al. (2026). “Plasma Phosphorylated Tau 217 and Incident Mild Cognitive Impairment and Dementia in Older Women.” JAMA Network Open.
- University of California San Diego: “Blood Test Predicts Dementia in Women as Many as 25 Years Before Symptoms Begin” (March 10, 2026).
- Press Trust of India (PTI): “Blood biomarker may help predict woman’s dementia risk 25 years before symptoms: Study” (March 11, 2026).
- Times of San Diego: “Blood test signals dementia risk in women decades before symptoms, UCSD study finds” (March 10, 2026).
Leave a Reply